Patents by Inventor Michael Kormann

Michael Kormann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Permanent gene correction by means of nucleotide-modified messenger RNA
    Patent number: 11332726
    Abstract: The present invention relates to a nucleotide-modified messenger RNA for the permanent correction of a genetic alteration on a DNA. The invention further relates to a nucleotide-modified messenger RNA in combination with a repair template. It also relates to a pharmaceutical composition. It finally relates to methods for the correction of a genetic alteration on a DNA.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: May 17, 2022
    Assignees: EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄT, HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH FÜR DAS HELMHOLTZ-INSTITUT FÜR PHARMAZEUTISCHE FORSCHUNG SAARLAND (HIPS)
    Inventors: Michael Kormann, Lauren Mays Weddle, Claus-Michael Lehr, Brigitta Loretz, Emad Malaeksefat
  • RNA WITH A COMBINATION OF UNMODIFIED AND MODIFIED NUCLEOTIDES FOR PROTEIN EXPRESSION
    Publication number: 20210095272
    Abstract: The invention relates to a polyribonucleotide with a sequence that codes a protein or protein fragment, wherein the polyribonucleotide comprises a combination of unmodified and modified nucleotide, wherein 5 to 50% of the uridine nucleotides and 5 to 50% of the cytidin nucleotides are modified uridine nucleotides or modified cytidin nucleotides.
    Type: Application
    Filed: July 8, 2020
    Publication date: April 1, 2021
    Inventors: Carsten Rudolph, Michael Kormann
  • RNA with a combination of unmodified and modified nucleotides for protein expression
    Patent number: 10745698
    Abstract: The invention relates to a polyribonucleotide with a sequence that codes a protein or protein fragment, wherein the polyribonucleotide comprises a combination of unmodified and modified nucleotides, wherein 5 to 50% of the uridine nucleotides and 5 to 50% of the cytidin nucleotides are modified uridine nucleotides or modified cytidin nucleotides.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: August 18, 2020
    Assignee: ETHRIS GMBH
    Inventors: Carsten Rudolph, Michael Kormann
  • RNA BASED BIOMATERIAL FOR TISSUE ENGINEERING APPLICATIONS
    Publication number: 20200222559
    Abstract: The present disclosure provides compositions and methods useful for tissue engineering including a composition having chemically modified RNA (cmRNA) encapsulated in or complexed with a non-viral delivery vehicle and a biocompatible, bioresorbable scaffold and methods of using the composition to regenerate, for example, bone tissue.
    Type: Application
    Filed: May 30, 2019
    Publication date: July 16, 2020
    Inventors: Satheesh Elangovan, Sheetal Reginald R. D'mello, Anh-Vu T. Do, Liu Hong, Behnoush Khorsand-Sourkohi, Aliasger K. Salem, Michael Kormann
  • CHEMICALLY MODIFIED mRNA FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH THE CFTR GENE
    Publication number: 20200061098
    Abstract: A chemically modified mRNA, a nucleic acid molecule encoding the CFTR cmRNA, a vector including the nucleic acid molecule, a host cell including the vector, or a pharmaceutical composition including the CFTR cmRNA, nucleic acid molecule or vector can be used in a method for the treatment of a disease associated with the CFTR gene.
    Type: Application
    Filed: November 4, 2019
    Publication date: February 27, 2020
    Inventors: Michael Kormann, Alexander Dewerth, Ashiqul Haque, Justin S. Antony
  • PERMANENT GENE CORRECTION BY MEANS OF NUCLEOTIDE-MODIFIED MESSENGER RNA
    Publication number: 20190376051
    Abstract: The present invention relates to a nucleotide-modified messenger RNA for the permanent correction of a genetic alteration on a DNA. The invention further relates to a nucleotide-modified messenger RNA in combination with a repair template. It also relates to a pharmaceutical composition. It finally relates to methods for the correction of a genetic alteration on a DNA.
    Type: Application
    Filed: April 30, 2019
    Publication date: December 12, 2019
    Applicants: Eberhard Karls Universität Tübingen Medizinische Fakultät, Helmholtz-Zentrum für Infektionsforschung GmbH für das Helmholtz-Institut für Pharmazeutische
    Inventors: Michael KORMANN, Lauren Mays WEDDLE, Claus-Michael LEHR, Brigitta LORETZ, Emad MALAEKSEFAT
  • RNA based biomaterial for tissue engineering applications
    Patent number: 10335498
    Abstract: The present disclosure provides compositions and methods useful for tissue engineering including a composition having chemically modified RNA (cmRNA) encapsulated in or complexed with a non-viral delivery vehicle and a biocompatible, bioresorbable scaffold and methods of using the composition to regenerate, for example, bone tissue.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: July 2, 2019
    Assignee: University of Iowa Research Foundation
    Inventors: Satheesh Elangovan, Sheetal Reginald R D'mello, Anh-Vu T Do, Liu Hong, Behnoush Khorsand-Sourkohi, Aliasger K Salem, Michael Kormann
  • TARGETED MRNA FOR IN VIVO APPLICATION
    Publication number: 20190040392
    Abstract: A medicament can include a product for in vivo expression of a protein in a living being. The product can include a first entity, which includes a nucleic acid encoding an intracellularly expressible protein, and an associated second entity configured for specific binding to a cellular structure of the living being. One example of the product is a nucleotide-modified mRNA, in which includes a first ribonucleotide sequence encoding the intracellularly expressible protein, and a second ribonucleotide sequence encoding an aptamer configured for specific binding to the cellular structure of the living being.
    Type: Application
    Filed: October 19, 2018
    Publication date: February 7, 2019
    Inventors: Michael Kormann, Christian Martin Seitz, Patrick Schlegel
  • PERMANENT GENE CORRECTION BY MEANS OF NUCLEOTIDE-MODIFIED MESSENGER RNA
    Publication number: 20160298099
    Abstract: The present invention relates to a nucleotide-modified messenger RNA for the permanent correction of a genetic alteration on a DNA. The invention further relates to a nucleotide-modified messenger RNA in combination with a repair template. It also relates to a pharmaceutical composition. It finally relates to methods for the correction of a genetic alteration on a DNA.
    Type: Application
    Filed: April 8, 2016
    Publication date: October 13, 2016
    Applicant: Eberhard Karls Universitat Tubingen Medizinische F akultat
    Inventors: Michael KORMANN, Lauren MAYS
  • RNA WITH A COMBINATION OF UNMODIFIED AND MODIFIED NUCLEOTIDES FOR PROTEIN EXPRESSION
    Publication number: 20160177295
    Abstract: The invention relates to a polyribonucleotide with a sequence that codes a protein or protein fragment, wherein the polyribonucleotide comprises a combination of unmodified and modified nucleotides, wherein 5 to 50% of the uridine nucleotides and 5 to 50% of the cytidin nucleotides are modified uridine nucleotides or modified cytidin nucleotides.
    Type: Application
    Filed: August 28, 2015
    Publication date: June 23, 2016
    Inventors: Carsten Rudolph, Michael Kormann
  • RNA WITH A COMBINATION OF UNMODIFIED AND MODIFIED NUCLEOTIDES FOR PROTEIN EXPRESSION
    Publication number: 20150291678
    Abstract: The invention relates to a polyribonucleotide with a sequence that codes a protein or protein fragment, wherein the polyribonucleotide comprises a combination of unmodified and modified nucleotides, wherein 5 to 50% of the uridine nucleotides and 5 to 50% of the cytidine nucleotides are modified uridine nucleotides or modified cytidine nucleotides.
    Type: Application
    Filed: April 27, 2015
    Publication date: October 15, 2015
    Applicant: ETHRIS GMBH
    Inventors: Carsten RUDOLPH, Michael Kormann
  • RNA WITH A COMBINATION OF UNMODIFIED AND MODIFIED NUCLEOTIDES FOR PROTEIN EXPRESSION
    Publication number: 20150290288
    Abstract: The invention relates to a polyribonucleotide with a sequence that codes a protein or protein fragment, wherein the polyribonucleotide comprises a combination of unmodified and modified nucleotides, wherein 5 to 50% of the uridine nucleotides and 5 to 50% of the cytidin nucleotides are modified uridine nucleotides or modified cytidin nucleotides.
    Type: Application
    Filed: February 20, 2015
    Publication date: October 15, 2015
    Applicant: ethris Gmbh
    Inventors: Carsten RUDOLPH, Michael Kormann
  • RNA WITH A COMBINATION OF UNMODIFIED AND MODIFIED NUCLEOTIDES FOR PROTEIN EXPRESSION
    Publication number: 20150258174
    Abstract: The invention relates to a polyribonucleotide with a sequence that codes a protein or protein fragment, wherein the polyribonucleotide comprises a combination of unmodified and modified nucleotides, wherein 5 to 50% of the uridine nucleotides and 5 to 50% of the cytidin nucleotides are modified uridine nucleotides or modified cytidin nucleotides.
    Type: Application
    Filed: February 20, 2015
    Publication date: September 17, 2015
    Applicant: ethris Gmbh
    Inventors: Carsten RUDOLPH, Michael Kormann
  • RNA WITH A COMBINATION OF UNMODIFIED AND MODIFIED NUCLEOTIDES FOR PROTEIN EXPRESSION
    Publication number: 20120195936
    Abstract: The invention relates to a polyribonucleotide with a sequence that codes a protein or protein fragment, wherein the polyribonucleotide comprises a combination of unmodified and modified nucleotides, wherein 5 to 50% of the uridine nucleotides and 5 to 50% of the cytidin nucleotides are modified uridine nucleotides or modified cytidin nucleotides.
    Type: Application
    Filed: July 30, 2010
    Publication date: August 2, 2012
    Applicant: ETHRIS GMBH
    Inventors: Carsten Rudolph, Michael Kormann